<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The influence of Exisulind on the viability and <z:mpath ids='MPATH_3'>apoptosis</z:mpath> of CD34(+) stem cells from patients with advanced <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) and <z:hpo ids='HP_0011009'>acute</z:hpo> <z:mpath ids='MPATH_342'>myeloid leukaemia</z:mpath> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>)/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> was investigated </plain></SENT>
<SENT sid="1" pm="."><plain>In eight out of 10 patient samples Exisulind reduced the fraction of viable cells by inducing <z:mpath ids='MPATH_3'>apoptosis</z:mpath> </plain></SENT>
<SENT sid="2" pm="."><plain>We found evidence that Exisulind-mediated <z:mpath ids='MPATH_3'>apoptosis</z:mpath> depends on c-Jun NH(2)-terminal kinase (JNK) activation </plain></SENT>
<SENT sid="3" pm="."><plain>Addition of a specific JNK-inhibitor to Exisulind-treated advanced <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> and <z:e sem="disease" ids="C1332153" disease_type="Neoplastic Process" abbrv="">AML/MDS</z:e> cells partly abrogated <z:mpath ids='MPATH_3'>apoptosis</z:mpath> </plain></SENT>
<SENT sid="4" pm="."><plain>We propose that Exisulind is tested in clinical phase I/II trials for the treatment of advanced <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> and <z:e sem="disease" ids="C1332153" disease_type="Neoplastic Process" abbrv="">AML/MDS</z:e> </plain></SENT>
</text></document>